ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
60 899,43
0,17%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Sana Biotechnology Inc (SANA)

  7. Sana Biotechnology Inc (SANA) Actualités

SANA

Sana Biotechnology (SANA)

Sana Biotechnology Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SANA
DateHeureSourceTitreSymboleSociété
08/05/202422h49Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SANASana Biotechnology Inc
08/05/202422h21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SANASana Biotechnology Inc
08/05/202422h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
08/05/202422h05GlobeNewswire Inc.Sana Biotechnology Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
06/05/202422h05GlobeNewswire Inc.Sana Biotechnology to Present at May and June 2024 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
08/03/202422h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SANASana Biotechnology Inc
29/02/202422h05GlobeNewswire Inc.Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
28/02/202422h05GlobeNewswire Inc.Sana Biotechnology to Present at the Cowen 44th Annual Health Care ConferenceNASDAQ:SANASana Biotechnology Inc
14/02/202422h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SANASana Biotechnology Inc
13/02/202422h05GlobeNewswire Inc.Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHPNASDAQ:SANASana Biotechnology Inc
12/02/202422h05GlobeNewswire Inc.Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:SANASana Biotechnology Inc
08/02/202422h49Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SANASana Biotechnology Inc
08/02/202407h22GlobeNewswire Inc.Sana Biotechnology Announces Pricing of Upsized Public OfferingNASDAQ:SANASana Biotechnology Inc
08/02/202403h59Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:SANASana Biotechnology Inc
07/02/202422h01GlobeNewswire Inc.Sana Biotechnology Announces Proposed Public Offering of Common StockNASDAQ:SANASana Biotechnology Inc
05/01/202415h00GlobeNewswire Inc.Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell MalignanciesNASDAQ:SANASana Biotechnology Inc
03/01/202422h05GlobeNewswire Inc.Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SANASana Biotechnology Inc
15/12/202322h34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SANASana Biotechnology Inc
11/12/202315h00GlobeNewswire Inc.Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual MeetingNASDAQ:SANASana Biotechnology Inc
01/12/202322h05GlobeNewswire Inc.Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune SystemNASDAQ:SANASana Biotechnology Inc
28/11/202301h01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science LeadersNASDAQ:SANASana Biotechnology Inc
21/11/202315h00GlobeNewswire Inc.Sana Biotechnology to Present at November and December 2023 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
21/11/202312h00PR Newswire (US)Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsNASDAQ:SANASana Biotechnology Inc
17/11/202315h00GlobeNewswire Inc.Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 DiabetesNASDAQ:SANASana Biotechnology Inc
09/11/202322h05GlobeNewswire Inc.Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated VasculitisNASDAQ:SANASana Biotechnology Inc
08/11/202322h05GlobeNewswire Inc.Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
02/11/202314h05GlobeNewswire Inc.Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual MeetingNASDAQ:SANASana Biotechnology Inc
01/11/202315h30PR Newswire (US)Flagship Pioneering Launches Pioneering IntelligenceNASDAQ:SANASana Biotechnology Inc
10/10/202322h15GlobeNewswire Inc.Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200MNASDAQ:SANASana Biotechnology Inc
11/09/202312h30PR Newswire (US)Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerNASDAQ:SANASana Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:SANA

Dernières Valeurs Consultées

EU
MC
Lvmh Moet Hennessy Louis...
NASDAQ
AMZN
Amazon.com
EU
BNP
BNP Paribas
EU
AF
Air FranceKLM
EU
VK
Vallourec
NASDAQ
GOOGL
Alphabet
EU
LR
Legrand
EU
HO
Thales
EU
ACA
Credit Agricole
EU
VIV
Vivendi
EU
DG
Vinci
EU
SGO
Cie de SaintGobain
SPI
SP500
S&P 500
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés